Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Disease overview

PART 06: Key clinical trials

PART 07: Market dynamics

PART 08: Market landscape

Market overview

Five forces analysis

PART 09: Market segmentation by drug-class

Global calcium channel blockers market

Global beta-adrenergic blockers market

Global antiarrhythmic market

Global anticoagulants market

PART 10: Geographical segmentation

HCM therapeutics market in Americas

HCM therapeutics market in EMEA

HCM therapeutics market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

Market drivers

Market challenges

Impact of drivers and challenges on key customer

segments (hospitals and pharmacies)

PART 13: Market trends

Increasing availability of genetic tests

Development of TBI

Advent of genomic medicine

PART 14: Vendor landscape

Competitive landscape

PART 15: Key vendor analysis

AstraZeneca

Merck

Pfizer

Sanofi

Other prominent vendors

PART 16: Appendix

List of abbreviations